Exclusive Summary

• The highly differentiated Powder-Liquid Double-Chamber Bag (Ready-To-Use) formulation eliminates admixture contamination risks and saves crucial ICU nursing time, providing a strong competitive edge.
• Meropenem is a WHO Essential Medicine and the gold-standard first-line therapy targeting a massive critical need, effectively addressing over 48 million global sepsis cases and ESBL-producing bacterial infections annually.
• The scheduled EU GMP inspection in Q4 2026 allows overseas partners to lock in high-quality capacity now and initiate regulatory submissions for EU and PIC/S member states concurrently.
• Backed by China's integrated supply chain advantage, it provides a high-end closed-loop delivery system at a highly competitive cost, ensuring significant margin potential compared to originators and regional RTU rivals.